ID   CDN2A_RAT               Reviewed;         159 AA.
AC   Q9R0Z3;
DT   11-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   02-OCT-2024, entry version 137.
DE   RecName: Full=Cyclin-dependent kinase inhibitor 2A {ECO:0000312|RGD:2323};
DE   AltName: Full=Cyclin-dependent kinase 4 inhibitor A;
DE            Short=CDK4I;
DE   AltName: Full=p16-INK4a;
DE            Short=p16;
DE            Short=p16-INK4;
GN   Name=Cdkn2a {ECO:0000312|EMBL:AAL76338.1, ECO:0000312|RGD:2323};
GN   Synonyms=P16ink4a {ECO:0000250|UniProtKB:P51480};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAD48924.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   STRAIN=Fischer 344/N; TISSUE=Lung {ECO:0000312|EMBL:AAD48924.1};
RX   PubMed=9032263; DOI=10.1128/mcb.17.3.1366;
RA   Swafford D.S., Middleton S.K., Palmisano W.A., Nikula K.J., Tesfaigzi J.,
RA   Baylin S.B., Herman J.G., Belinsky S.A.;
RT   "Frequent aberrant methylation of p16INK4a in primary rat lung tumors.";
RL   Mol. Cell. Biol. 17:1366-1374(1997).
RN   [2] {ECO:0000312|EMBL:AAL76338.1}
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=ACI/SegHsd {ECO:0000312|EMBL:AAL76338.1},
RC   Brown Norway/SsNHsd {ECO:0000312|EMBL:AAT92510.1}, and
RC   COP {ECO:0000312|EMBL:AAL76339.1};
RC   TISSUE=Spleen {ECO:0000312|EMBL:AAL76338.1};
RA   Buckles L.K., Shull J.D.;
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a negative regulator of the proliferation of normal
CC       cells by interacting strongly with CDK4 and CDK6. This inhibits their
CC       ability to interact with cyclins D and to phosphorylate the
CC       retinoblastoma protein (By similarity). {ECO:0000250|UniProtKB:P51480}.
CC   -!- SUBUNIT: Heterodimer with CDK4 or CDK6. Predominamt P16 complexes
CC       contained CDK6. Interacts with CDK4 (both 'T-172'-phosphorylated and
CC       non-phosphorylated forms); the interaction inhibits cyclin D-CDK4
CC       kinase activity. Interacts with ISCO2 (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Isoform 1 and isoform tumor suppressor ARF arise due to the
CC         use of two alternative first exons joined to a common exon 2 at the
CC         same acceptor site but in different reading frames, resulting in two
CC         completely different isoforms. {ECO:0000250|UniProtKB:P51480};
CC       Name=1 {ECO:0000269|PubMed:9032263}; Synonyms=p16INK4a
CC       {ECO:0000250|UniProtKB:P51480};
CC         IsoId=Q9R0Z3-1; Sequence=Displayed;
CC       Name=tumor suppressor ARF {ECO:0000305}; Synonyms=p19ARF {ECO:0000305};
CC         IsoId=Q8QZZ9-1; Sequence=External;
CC   -!- TISSUE SPECIFICITY: Expressed in spleen, liver and lung. Not detected
CC       in kidney, colon, stomach or brain. {ECO:0000269|PubMed:9032263}.
CC   -!- PTM: Phosphorylation seems to increase interaction with CDK4.
CC       {ECO:0000250}.
CC   -!- MISCELLANEOUS: Down-regulated in a number of tumor cell lines in
CC       response to methylation of the CpG island in exon 1.
CC       {ECO:0000269|PubMed:9032263}.
CC   -!- SIMILARITY: Belongs to the CDKN2 cyclin-dependent kinase inhibitor
CC       family. {ECO:0000255}.
CC   -!- CAUTION: The proteins described here are encoded by the gene CDKN2A,
CC       but are completely unrelated in terms of sequence and function to tumor
CC       suppressor ARF (AC Q8QZZ9) which is encoded by the same gene.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L81167; AAD48924.1; -; mRNA.
DR   EMBL; AF474976; AAL76338.1; -; mRNA.
DR   EMBL; AF474977; AAL76339.1; -; mRNA.
DR   EMBL; AY679728; AAT92510.1; -; mRNA.
DR   RefSeq; NP_113738.1; NM_031550.1. [Q9R0Z3-1]
DR   AlphaFoldDB; Q9R0Z3; -.
DR   SMR; Q9R0Z3; -.
DR   PhosphoSitePlus; Q9R0Z3; -.
DR   PaxDb; 10116-ENSRNOP00000061040; -.
DR   Ensembl; ENSRNOT00000103638.1; ENSRNOP00000087870.1; ENSRNOG00000059837.2. [Q9R0Z3-1]
DR   Ensembl; ENSRNOT00065032552; ENSRNOP00065025981; ENSRNOG00065019345. [Q9R0Z3-1]
DR   GeneID; 25163; -.
DR   KEGG; rno:25163; -.
DR   AGR; RGD:2323; -.
DR   CTD; 1029; -.
DR   RGD; 2323; Cdkn2a.
DR   eggNOG; KOG0504; Eukaryota.
DR   GeneTree; ENSGT00940000165099; -.
DR   OrthoDB; 2321802at2759; -.
DR   Proteomes; UP000002494; Chromosome 5.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0001652; C:granular component; ISO:RGD.
DR   GO; GO:0005730; C:nucleolus; ISO:RGD.
DR   GO; GO:0005654; C:nucleoplasm; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0035985; C:senescence-associated heterochromatin focus; ISO:RGD.
DR   GO; GO:0004861; F:cyclin-dependent protein serine/threonine kinase inhibitor activity; ISO:RGD.
DR   GO; GO:0097718; F:disordered domain specific binding; ISO:RGD.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; ISO:RGD.
DR   GO; GO:0051059; F:NF-kappaB binding; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; ISO:RGD.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0019789; F:SUMO transferase activity; ISO:RGD.
DR   GO; GO:1990948; F:ubiquitin ligase inhibitor activity; ISO:RGD.
DR   GO; GO:0055105; F:ubiquitin-protein transferase inhibitor activity; ISO:RGD.
DR   GO; GO:1990000; P:amyloid fibril formation; ISO:RGD.
DR   GO; GO:0008637; P:apoptotic mitochondrial changes; ISO:RGD.
DR   GO; GO:0060057; P:apoptotic process involved in mammary gland involution; ISO:RGD.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEP:RGD.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; ISO:RGD.
DR   GO; GO:0090398; P:cellular senescence; ISO:RGD.
DR   GO; GO:0021549; P:cerebellum development; IEP:RGD.
DR   GO; GO:0008544; P:epidermis development; ISO:RGD.
DR   GO; GO:0042593; P:glucose homeostasis; ISO:RGD.
DR   GO; GO:0030216; P:keratinocyte differentiation; ISO:RGD.
DR   GO; GO:0043616; P:keratinocyte proliferation; ISO:RGD.
DR   GO; GO:0033598; P:mammary gland epithelial cell proliferation; ISO:RGD.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; ISO:RGD.
DR   GO; GO:0045786; P:negative regulation of cell cycle; ISO:RGD.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISO:RGD.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; ISO:RGD.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; ISO:RGD.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:2000346; P:negative regulation of hepatocyte proliferation; IMP:RGD.
DR   GO; GO:0033088; P:negative regulation of immature T cell proliferation in thymus; ISO:RGD.
DR   GO; GO:0033600; P:negative regulation of mammary gland epithelial cell proliferation; ISO:RGD.
DR   GO; GO:1904750; P:negative regulation of protein localization to nucleolus; ISO:RGD.
DR   GO; GO:2000435; P:negative regulation of protein neddylation; ISO:RGD.
DR   GO; GO:1903051; P:negative regulation of proteolysis involved in protein catabolic process; ISO:RGD.
DR   GO; GO:0090071; P:negative regulation of ribosome biogenesis; ISO:RGD.
DR   GO; GO:2000059; P:negative regulation of ubiquitin-dependent protein catabolic process; ISO:RGD.
DR   GO; GO:0022008; P:neurogenesis; IEP:RGD.
DR   GO; GO:0090402; P:oncogene-induced cell senescence; ISO:RGD.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0060058; P:positive regulation of apoptotic process involved in mammary gland involution; ISO:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:2000111; P:positive regulation of macrophage apoptotic process; ISO:RGD.
DR   GO; GO:0033235; P:positive regulation of protein sumoylation; ISO:RGD.
DR   GO; GO:0034393; P:positive regulation of smooth muscle cell apoptotic process; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0031648; P:protein destabilization; ISO:RGD.
DR   GO; GO:0070534; P:protein K63-linked ubiquitination; ISO:RGD.
DR   GO; GO:0000209; P:protein polyubiquitination; ISO:RGD.
DR   GO; GO:0050821; P:protein stabilization; ISO:RGD.
DR   GO; GO:0007265; P:Ras protein signal transduction; ISO:RGD.
DR   GO; GO:1902510; P:regulation of apoptotic DNA fragmentation; ISO:RGD.
DR   GO; GO:0051726; P:regulation of cell cycle; ISO:RGD.
DR   GO; GO:2000045; P:regulation of G1/S transition of mitotic cell cycle; ISO:RGD.
DR   GO; GO:0010468; P:regulation of gene expression; ISO:RGD.
DR   GO; GO:0046822; P:regulation of nucleocytoplasmic transport; ISO:RGD.
DR   GO; GO:0031647; P:regulation of protein stability; ISO:RGD.
DR   GO; GO:0090399; P:replicative senescence; ISO:RGD.
DR   GO; GO:0061771; P:response to caloric restriction; IEP:RGD.
DR   GO; GO:0070542; P:response to fatty acid; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IDA:RGD.
DR   GO; GO:0009651; P:response to salt stress; IEP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IDA:RGD.
DR   GO; GO:0009303; P:rRNA transcription; ISO:RGD.
DR   GO; GO:0048103; P:somatic stem cell division; ISO:RGD.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; ISO:RGD.
DR   Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1.
DR   InterPro; IPR050776; Ank_Repeat/CDKN_Inhibitor.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   PANTHER; PTHR24201; ANK_REP_REGION DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR24201:SF8; CYCLIN-DEPENDENT KINASE 4 INHIBITOR B; 1.
DR   Pfam; PF00023; Ank; 1.
DR   Pfam; PF12796; Ank_2; 1.
DR   SMART; SM00248; ANK; 4.
DR   SUPFAM; SSF48403; Ankyrin repeat; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
PE   2: Evidence at transcript level;
KW   Alternative splicing; ANK repeat; Cell cycle; Cytoplasm; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Tumor suppressor.
FT   CHAIN           1..159
FT                   /note="Cyclin-dependent kinase inhibitor 2A"
FT                   /id="PRO_0000144179"
FT   REPEAT          3..35
FT                   /note="ANK 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          36..64
FT                   /note="ANK 2"
FT                   /evidence="ECO:0000255"
FT   REPEAT          69..98
FT                   /note="ANK 3"
FT                   /evidence="ECO:0000255"
FT   REPEAT          102..134
FT                   /note="ANK 4"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         143
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P42771"
SQ   SEQUENCE   159 AA;  17366 MW;  3C4CA920A1FEAEB6 CRC64;
     MESSADRLAR AAALGREHEV RALLEAGASP NAPNTFGRTP IQVMMMGNVK VAALLLSYGA
     DSNCEDPTTL SRPVHDAARE GFLDTLVVLH QAGARLDVRD AWGRLPLDLA LERGHHDVVR
     YLRYLLSSAG NVSRVTDRHN FCSSTPRCLG LRGQPPKQR
//
